In chronic hepatitis C virus (HCV) infection, it has previously been shown that patients with strong ISG‐signatures have a lower chance of responding to treatment with IFNα, clearly demonstrating the in vivo relevance of interferon pathway desensitization (Chen et al, 2005). The gene discussed is IFNA1; the disease is chronic hepatitis.